Winship Cancer Institute of Emory University | Strategic Alliance Partners

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

Adam Marcus, PhD, has been appointed interim executive director of Winship Cancer Institute of Emory University, the National Cancer Institute–designated comprehensive cancer center for Georgia.

Sagar Lonial MD, FACP, discusses unanswered questions with T-cell engagers in myeloma.

Suresh S. Ramalingam, MD, FASCO, discusses limitations with immunotherapy in non–small cell lung cancer.

In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

Data from a subgroup analysis of the phase 2 GRIFFIN study demonstrated that adding daratumumab to lenalidomide, bortezomib, and dexamethasone improved depth of response, stringent complete response, and minimal residual disease negativity, in Black patients with newly diagnosed multiple myeloma.

Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.

Sagar Lonial, MD, FACP, discusses the approval of belantamab mafodotin-blmf and how it addressed an unmet need in relapsed/refractory multiple myeloma.

Nabil F. Saba, MD, FACP, discusses ​scheduling challenges with cisplatin in head and neck cancer.

Nabil F. Saba, MD, FACP, discusses ​emerging sequencing ​strategies in head and neck cancer. 

Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Nabil F. Saba, MD, FACP, discusses the future of treatment in head and neck cancer.

Sagar Lonial, MD, FACP, discusses the benefits of early intervention in high-risk smoldering multiple myeloma.

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses the impact of the coronavirus disease 2019 (COVID-19) on telehealth in head and neck cancer.

Nabil F. Saba, MD, FACP, discusses how the COVID-19 pandemic has impacted treatment in head and neck cancer and the health care system at large.

Ragini R. Kudchadkar, MD, discusses the biological differences between ocular melanoma and cutaneous melanoma.

Obese men with nonmetastatic prostate cancer have higher cardiovascular disease–related mortality and all-cause mortality, and potentially increased prostate cancer–specific mortality.

Ragini Kudchadkar, MD, discusses the prognosis of patients with metastatic ocular melanoma and the work being done to define novel approaches in melanoma.

Walter J. Curran, Jr, MD, FACR, FASCO, explains the eligibility criteria for immunotherapy and radiation in patients with lung cancer.

Sagar Lonial, MD, FACP, discusses the role of targeted therapy in acute myeloid leukemia and acute lymphoblastic leukemia.

Sagar Lonial, MD, FACP, discusses the encouraging activity with the BCMA-targeted agent belantamab mafodotin in multiple myeloma.

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

Jean L. Koff, MD, MS, discusses systemic therapies in follicular lymphoma.

Pamela Blair Allen, MD, MSc, discusses treatment options in advanced-stage Hodgkin lymphoma.

Martha L. Arellano, MD, discusses the management of older patients with acute myeloid leukemia.

Sagar Lonial, MD, FACP, discusses the ICARIA-MM trial in patients with multiple myeloma who experience early relapse, have been heavily pretreated, or have refractory disease.

Jean L. Koff, MD, MS, highlights exciting advances made in follicular lymphoma and the promise of CAR T-cell therapies in other lymphoma subtypes.

William G. Blum, MD, discusses the introduction of novel agents into acute myeloid leukemia treatment and how this is impacting the role of molecular testing for patients.

Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.